BioForum: Biosimilars - Pioneering the Future

March 08, 2012 - On 24th May 2012 in Brno, Czech Republic, during BioForum, one of the keynote speakers - Dr. Steffen Wagner, Head Commercial Operations Central & Eastern Europe at Sandoz – will present a talk: “Biosimilars – Pioneering the Future”. Dr. Wagner, formerly Director Global Strategic Planning at Sandoz and Engagement Manager with McKinsey and Company’s Pharmaceutical Industry Practice, will discuss the development process, key challenges, regulatory environment, requirements for successful commercialization and key success factors for companies in the field.

Mark McCamish Presents Sandoz perspective on FDA biosimilar guidelines on BioCentury TV

February 23, 2012 - Mark McCamish, Head of Global Biopharmaceutical Development at Sandoz, was invited by BioCentury TV to present the industry perspective on the FDA’s new biosimilar guidance document.

Enoxaparin gives Sandoz injectables lead

Generics Bulletin, p.5, February 03, 2012 - Sandoz claims it is now the world’s leading supplier of generic injectables after 2011 sales of its US rival to Sanofi’s Lovenox (enoxaparin) narrowly exceeded annual sales of US$1.0 billion. Retail sales of the firm’s anti-infective injectables rose by a tenth last year, while it also benefitted from the roster of oncology drugs acquired by paying US$1.3 billion for Austria’s Ebewe Pharma in September 2009.

Hexal moves into tenders

Generics Bulletin, p.23, February 03, 2012 - When Germany’s AOK group of statutory health insurance funds announced the results of its seventh round of tender contracts in late- November last year, Sandoz grabbed the headlines for more than one reason. Novartis’ generics business led the way by capturing 145 of the 737 regional supply contracts awarded, ahead of Stada in second place on 127 contracts and Teva in third with 118 of the contracts handed out by the fund, which accounts for just over a third of Germany’s statutory health insurance market.